triumph-1 trial retatrutide results: Retatrutide, the triple agonist. Significant weight loss ( 28.3% average loss at 80 weeks). It has potential to transform obesity treatment with results comparable to… Everyone is calling retatrutide a

These improvements may also impact the broader medical insurance sector, potentially leading to both reduced premiums and reduced claims burdens

This is also a good time for your first body composition assessment (DEXA scan or equivalent)

Highmark Medicare Advantage members pursuing the cardiovascular indication under J-1370 cannot use the savings card

The SUSTAIN-6 CVOT [67], performed in 3,297 patients with T2DM and ASCVD/CKD, has shown that compared to placebo, semaglutide was associated with increased retinopathy complications (3.0% versus 1.8%

That extra pathway is one reason researchers are interested in retatrutide, but it is also a reason not to assume its risk profile is identical to tirzepatides

Tirzepatide adds GIP receptor activation, making it a dual agonist